ADC Therapeutics SA expected to post a loss of 47 cents a share - Earnings Preview

• ADC Therapeutics SA ADCT, ADCT is expected to show a rise in quarterly revenue when it reports results on August 4 (estimated) for the period ending June 30 2025

• The Epalinges Vaud-based company is expected to report a 2.6% increase in revenue to $17.861 million from $17.41 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.

• ​LSEG's mean analyst estimate for ADC Therapeutics SA is for a loss of 47 cents per share.

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The mean earnings estimate of analysts was unchanged in the last three months. ​

• Wall Street's median 12-month price target for ADC Therapeutics SA is $9.00, about 69.2% above its last closing price of $2.77

Previous quarterly performance (using preferred earnings measure in US dollars). ​

This summary was machine generated August 1 at 13:09 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)